News
Pfizer, Moderna and BioNTech
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent. This decision affirms the High Court’s initial ruling from July 2024 that the EP’949 patent is valid and infringed by Pfizer/BioNTech’s COVID-19 vaccine,
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as ...
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results